This result reflects
- Solid growth in the immunoglobulin portfolio
- Successful evolution of the haemophilia portfolio
- Transition to our own distribution model in China
- Delivery on the product differentiation strategy with strong profit growth for Seqirus
- No material revenue impact to date resulting from the COVID-19 pandemic; however, the situation is fluid and some elements are unpredictable
Mr Paul Perreault, CSL’s Chief Executive Officer and Managing Director said, “I am pleased to report an exceptional result against a backdrop of complex and unexpected challenges brought about by the COVID-19 pandemic.”
Read about our CSL 2019/2020 Financial Results as well as the full ASX announcement including operational highlights and outlook on CSL.com.
[1] All figures in US dollars unless stated otherwise
[2] Constant currency (CC) removes the impact of exchange rate movements, facilitating comparability of operational performance. For further details please refer to CSL’s Financial Statements for the Full Year ended June 2020 (Directors’ Report).
" I am pleased to report an exceptional result against a backdrop of complex and unexpected challenges brought about by the COVID-19 pandemic. "
Paul Perreault, CSL’s Chief Executive Officer and Managing Director
